Tyrosine kinase inhibitors (TKI) have clinical utility as the standard first-line therapy drugs for NSCLC patients with mutations in genes encoding epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) (Drusbosky et al., 2021; Nagasaka et al., 2021; Popat et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.